Mankind Pharma Q2 Profit Up 29%, Revenue Rises 13.6%
By Rediff Money Desk, New Delhi Nov 05, 2024 20:10
Mankind Pharma's net profit surged 29% to Rs 659 cr in Q2 FY25, driven by volume recovery and strong EBITDA margins. Revenue grew 13.6% to Rs 3,076 cr.
New Delhi, Nov 5 (PTI) Mankind Pharma on Tuesday reported a 29 per cent rise in its consolidated net profit to Rs 658.88 crore for the second quarter ended September 2024, helped by recovery in volume.
The company posted a net profit of Rs 511.18 crore in the July-September quarter a year ago, according to a regulatory filing from Mankind Pharma, the country's fourth largest pharmaceutical company.
Its revenue from operations increased 13.6 per cent to Rs 3,076.51 crore in the September quarter against Rs 2,708.10 crore a year ago.
The company had a "steady revenue growth of 13.6 per cent year-on-year with strong EBITDA margins of 27.7 per cent, driven by recovery in volume, continued outperformance in chronic segment and operating leverage," its Vice Chairman and Managing Director Rajeev Juneja said.
Its total expenses rose 9.8 per cent to Rs 2,339.19 crore in Q2 FY25.
The total income of Mankind Pharma, which includes other income, surged 15.09 per cent to Rs 3,185.94 crore in the September quarter.
Its domestic revenue increased 11 per cent to Rs 2,796 crore, while exports jumped 57 per cent to Rs 281 crore, Mankind Pharma said in its earnings statement.
Exports revenue was "driven by an increase in our base business supported by new launches in last 12-24 months", it said.
Shares of Mankind Pharma on Tuesday settled at Rs 2,714.40 on BSE, down 0.75 per cent from the previous close.
The company posted a net profit of Rs 511.18 crore in the July-September quarter a year ago, according to a regulatory filing from Mankind Pharma, the country's fourth largest pharmaceutical company.
Its revenue from operations increased 13.6 per cent to Rs 3,076.51 crore in the September quarter against Rs 2,708.10 crore a year ago.
The company had a "steady revenue growth of 13.6 per cent year-on-year with strong EBITDA margins of 27.7 per cent, driven by recovery in volume, continued outperformance in chronic segment and operating leverage," its Vice Chairman and Managing Director Rajeev Juneja said.
Its total expenses rose 9.8 per cent to Rs 2,339.19 crore in Q2 FY25.
The total income of Mankind Pharma, which includes other income, surged 15.09 per cent to Rs 3,185.94 crore in the September quarter.
Its domestic revenue increased 11 per cent to Rs 2,796 crore, while exports jumped 57 per cent to Rs 281 crore, Mankind Pharma said in its earnings statement.
Exports revenue was "driven by an increase in our base business supported by new launches in last 12-24 months", it said.
Shares of Mankind Pharma on Tuesday settled at Rs 2,714.40 on BSE, down 0.75 per cent from the previous close.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Thinkink Picturez
- 1.94 (+ 4.86)
- 69820171
- Rajnish Wellness
- 1.78 (+ 4.09)
- 54627483
- G G Engineering
- 1.80 (+ 1.12)
- 53423097
- GTL Infrastructure
- 2.32 ( 0.00)
- 34510899
- Vodafone Idea L
- 8.10 ( -0.25)
- 34418651
MORE NEWS
Vodafone Idea Raises Rs 1,980 Cr Through...
Vodafone Idea's board has approved the issuance of up to 175.53 crore shares on a...
Noida International Airport Passes Validation...
Noida International Airport has successfully completed its validation flight, a crucial...
Adani Group to Invest Rs 7.5 Lakh Cr in Rajasthan
Adani Group announces plans to invest Rs 7.5 lakh crore in Rajasthan across various...